Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California. more
Time Frame | MRVI | Sector | S&P500 |
---|---|---|---|
1-Week Return | 12.28% | -2.27% | -0.57% |
1-Month Return | 0.71% | -3.96% | 1.21% |
3-Month Return | -32.42% | -9.7% | 7.57% |
6-Month Return | -26.93% | -3.37% | 11.45% |
1-Year Return | -4.38% | 3.71% | 28.48% |
3-Year Return | -85.89% | 3.8% | 29.52% |
5-Year Return | -81.01% | 39.78% | 90.66% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 143.14M | 284.10M | 799.24M | 883.00M | 288.94M | [{"date":"2019-12-31","value":16.21,"profit":true},{"date":"2020-12-31","value":32.17,"profit":true},{"date":"2021-12-31","value":90.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":32.72,"profit":true}] |
Cost of Revenue | 66.85M | 79.65M | 140.56M | 168.96M | 148.74M | [{"date":"2019-12-31","value":39.57,"profit":true},{"date":"2020-12-31","value":47.14,"profit":true},{"date":"2021-12-31","value":83.19,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":88.04,"profit":true}] |
Gross Profit | 76.29M | 204.45M | 658.68M | 714.04M | 140.20M | [{"date":"2019-12-31","value":10.68,"profit":true},{"date":"2020-12-31","value":28.63,"profit":true},{"date":"2021-12-31","value":92.25,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":19.63,"profit":true}] |
Gross Margin | 53.30% | 71.96% | 82.41% | 80.87% | 48.52% | [{"date":"2019-12-31","value":64.67,"profit":true},{"date":"2020-12-31","value":87.32,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.12,"profit":true},{"date":"2023-12-31","value":58.88,"profit":true}] |
Operating Expenses | 51.98M | 103.55M | 115.28M | 147.63M | 171.85M | [{"date":"2019-12-31","value":30.25,"profit":true},{"date":"2020-12-31","value":60.26,"profit":true},{"date":"2021-12-31","value":67.08,"profit":true},{"date":"2022-12-31","value":85.91,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 23.99M | 67.60M | 554.64M | 574.22M | (31.65M) | [{"date":"2019-12-31","value":4.18,"profit":true},{"date":"2020-12-31","value":11.77,"profit":true},{"date":"2021-12-31","value":96.59,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-5.51,"profit":false}] |
Total Non-Operating Income/Expense | (59.80M) | (52.83M) | (54.14M) | (40.82M) | 631.32M | [{"date":"2019-12-31","value":-9.47,"profit":false},{"date":"2020-12-31","value":-8.37,"profit":false},{"date":"2021-12-31","value":-8.58,"profit":false},{"date":"2022-12-31","value":-6.47,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (5.85M) | 81.70M | 530.76M | 551.47M | 617.74M | [{"date":"2019-12-31","value":-0.95,"profit":false},{"date":"2020-12-31","value":13.23,"profit":true},{"date":"2021-12-31","value":85.92,"profit":true},{"date":"2022-12-31","value":89.27,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | (652.00K) | 2.88M | 61.52M | 60.81M | 756.11M | [{"date":"2019-12-31","value":-0.09,"profit":false},{"date":"2020-12-31","value":0.38,"profit":true},{"date":"2021-12-31","value":8.14,"profit":true},{"date":"2022-12-31","value":8.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (5.20M) | 78.82M | 469.25M | 490.66M | (138.38M) | [{"date":"2019-12-31","value":-1.06,"profit":false},{"date":"2020-12-31","value":16.06,"profit":true},{"date":"2021-12-31","value":95.64,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-28.2,"profit":false}] |
Income From Continuous Operations | (5.20M) | 78.82M | 469.25M | 490.66M | 59.04M | [{"date":"2019-12-31","value":-1.06,"profit":false},{"date":"2020-12-31","value":16.06,"profit":true},{"date":"2021-12-31","value":95.64,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":12.03,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (5.20M) | 76.89M | 469.25M | 490.66M | (119.03M) | [{"date":"2019-12-31","value":-1.06,"profit":false},{"date":"2020-12-31","value":15.67,"profit":true},{"date":"2021-12-31","value":95.64,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-24.26,"profit":false}] |
EPS (Diluted) | - | 0.11 | 1.59 | 1.80 | (0.02) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":6.11,"profit":true},{"date":"2021-12-31","value":88.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1.11,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MRVI | |
---|---|
Cash Ratio | 9.14 |
Current Ratio | 10.74 |
Quick Ratio | 9.94 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MRVI | |
---|---|
ROA (LTM) | -1.61% |
ROE (LTM) | -42.93% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MRVI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.52 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.27 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MRVI | |
---|---|
Trailing PE | NM |
Forward PE | 370.37 |
P/S (TTM) | 5.17 |
P/B | 2.33 |
Price/FCF | 315 |
EV/R | 2.84 |
EV/Ebitda | 1.44 |
Maravai Lifesciences Holdings Inc (MRVI) share price today is $5.67
Yes, Indians can buy shares of Maravai Lifesciences Holdings Inc (MRVI) on Vested. To buy Maravai Lifesciences Holdings Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MRVI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Maravai Lifesciences Holdings Inc (MRVI) via the Vested app. You can start investing in Maravai Lifesciences Holdings Inc (MRVI) with a minimum investment of $1.
You can invest in shares of Maravai Lifesciences Holdings Inc (MRVI) via Vested in three simple steps:
The 52-week high price of Maravai Lifesciences Holdings Inc (MRVI) is $11.55. The 52-week low price of Maravai Lifesciences Holdings Inc (MRVI) is $4.28.
The price-to-earnings (P/E) ratio of Maravai Lifesciences Holdings Inc (MRVI) is
The price-to-book (P/B) ratio of Maravai Lifesciences Holdings Inc (MRVI) is 2.33
The dividend yield of Maravai Lifesciences Holdings Inc (MRVI) is 0.00%
The market capitalization of Maravai Lifesciences Holdings Inc (MRVI) is $1.46B
The stock symbol (or ticker) of Maravai Lifesciences Holdings Inc is MRVI